Generic Nilotinib - CML - Chronic myeloid leukemia
FDA Approves Nilotinib Formulation for Chronic Myeloid Leukemia
November 15, 2024, Oncology News Central
FDA Grants New Nilotinib Formulation Approval to Treat Adults With Chronic Myeloid Leukemia
November 15, 2024, Pharmacy Times
Xspray Pharma : HyNap-Nilo receives FDA Orphan Drug Designation for the treatment of Chronic Myeloid Leukemia
December 30, 2020, MarketScreener
November 15, 2024, Oncology News Central
FDA Grants New Nilotinib Formulation Approval to Treat Adults With Chronic Myeloid Leukemia
November 15, 2024, Pharmacy Times
Xspray Pharma : HyNap-Nilo receives FDA Orphan Drug Designation for the treatment of Chronic Myeloid Leukemia
December 30, 2020, MarketScreener